Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England

View ORCID ProfileHelen Ward, View ORCID ProfileGraham Cooke, View ORCID ProfileMatthew Whitaker, View ORCID ProfileRozlyn Redd, View ORCID ProfileOliver Eales, Jonathan C Brown, Katharine Collet, Emily Cooper, View ORCID ProfileAnna Daunt, Kathryn Jones, Maya Moshe, View ORCID ProfileMichelle Willicombe, View ORCID ProfileSophie Day, View ORCID ProfileChristina Atchison, View ORCID ProfileAra Darzi, View ORCID ProfileChristl A Donnelly, View ORCID ProfileSteven Riley, View ORCID ProfileDeborah Ashby, View ORCID ProfileWendy S Barclay, View ORCID ProfilePaul Elliott
doi: https://doi.org/10.1101/2021.02.26.21252512
Helen Ward
1School of Public Health, Imperial College London, UK
2MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, UK
4Imperial College Healthcare NHS Trust, UK
5National Institute for Health Research Imperial Biomedical Research Centre, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Helen Ward
  • For correspondence: h.ward@imperial.ac.uk g.cooke@imperial.ac.uk p.elliott@imperial.ac.uk
Graham Cooke
3Department of Infectious Disease, Imperial College London, UK
4Imperial College Healthcare NHS Trust, UK
5National Institute for Health Research Imperial Biomedical Research Centre, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Graham Cooke
Matthew Whitaker
1School of Public Health, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew Whitaker
Rozlyn Redd
1School of Public Health, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rozlyn Redd
Oliver Eales
1School of Public Health, Imperial College London, UK
2MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Oliver Eales
Jonathan C Brown
3Department of Infectious Disease, Imperial College London, UK
4Imperial College Healthcare NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katharine Collet
1School of Public Health, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Cooper
1School of Public Health, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Daunt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna Daunt
Kathryn Jones
1School of Public Health, Imperial College London, UK
5National Institute for Health Research Imperial Biomedical Research Centre, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maya Moshe
3Department of Infectious Disease, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Willicombe
3Department of Infectious Disease, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michelle Willicombe
Sophie Day
1School of Public Health, Imperial College London, UK
5National Institute for Health Research Imperial Biomedical Research Centre, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sophie Day
Christina Atchison
1School of Public Health, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christina Atchison
Ara Darzi
4Imperial College Healthcare NHS Trust, UK
6Institute of Global Health Innovation at Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ara Darzi
Christl A Donnelly
1School of Public Health, Imperial College London, UK
2MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, UK
7Department of Statistics, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christl A Donnelly
Steven Riley
1School of Public Health, Imperial College London, UK
2MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steven Riley
Deborah Ashby
1School of Public Health, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Deborah Ashby
Wendy S Barclay
3Department of Infectious Disease, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wendy S Barclay
Paul Elliott
1School of Public Health, Imperial College London, UK
4Imperial College Healthcare NHS Trust, UK
5National Institute for Health Research Imperial Biomedical Research Centre, UK
8MRC Centre for Environment and Health, School of Public Health, Imperial College London, UK
9Health Data Research (HDR) UK London at Imperial College
10UK Dementia Research Institute at Imperial College
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul Elliott
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background England has experienced high rates of SARS-CoV-2 infection during the COVID-19 pandemic, affecting in particular minority ethnic groups and more deprived communities. A vaccination programme began in England in December 2020, with priority given to administering the first dose to the largest number of older individuals, healthcare and care home workers.

Methods A cross-sectional community survey in England undertaken between 26 January and 8 February 2021 as the fifth round of the REal-time Assessment of Community Transmission-2 (REACT-2) programme. Participants completed questionnaires, including demographic details and clinical and COVID-19 vaccination histories, and self-administered a lateral flow immunoassay (LFIA) test to detect IgG against SARS-CoV-2 spike protein. There were sufficient numbers of participants to analyse antibody positivity after 21 days from vaccination with the PfizerBioNTech but not the AstraZeneca/Oxford vaccine which was introduced slightly later.

Results The survey comprised 172,099 people, with valid IgG antibody results from 155,172. The overall prevalence of antibodies (weighted to be representative of the population of England and adjusted for test sensitivity and specificity) in England was 13.9% (95% CI 13.7, 14.1) overall, 37.9% (37.2, 38.7) in vaccinated and 9.8% (9.6, 10.0) in unvaccinated people. The prevalence of antibodies (weighted) in unvaccinated people was highest in London at 16.9% (16.3, 17.5), and higher in people of Black (22.4%, 20.8, 24.1) and Asian (20.0%, 19.0, 21.0) ethnicity compared to white (8.5%, 8.3, 8.7) people. The uptake of vaccination by age was highest in those aged 80 years or older (93.5%). Vaccine confidence was high with 92.0% (91.9, 92.1) of people saying that they had accepted or intended to accept the offer. Vaccine confidence varied by age and ethnicity, with lower confidence in young people and those of Black ethnicity. Particular concerns were identified around pregnancy, fertility and allergies. In 971 individuals who received two doses of the Pfizer-BioNTech vaccine, the proportion testing positive was high across all age groups. Following a single dose of Pfizer-BioNTech vaccine after 21 days or more, 84.1% (82.2, 85.9) of people under 60 years tested positive (unadjusted) with a decreasing trend with increasing age, but high responses to a single dose in those with confirmed or suspected prior COVID at 90.1% (87.2, 92.4) across all age groups.

Conclusions There is uneven distribution of SARS-CoV-2 antibodies in the population with a higher burden in key workers and some minority ethnic groups, similar to the pattern in the first wave. Confidence in the vaccine programme is high overall although it was lower in some of the higher prevalence groups which suggests the need for improved communication about specific perceived risks. Two doses of Pfizer-BioNTech vaccine, or a single dose following previous infection, confers high levels of antibody positivity across all ages. Further work is needed to understand the relationship between antibody positivity, clinical outcomes such as hospitalisation, and transmission.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study was funded by the Department of Health and Social Care in England. HW is a National Institute for Health Research (NIHR) Senior Investigator and acknowledges support from NIHR Biomedical Research Centre of Imperial College NHS Trust, NIHR School of Public Health Research, NIHR Applied Research Collaborative North West London, and Wellcome Trust (UNS32973). GC is supported by an NIHR Professorship. WSB is the Action Medical Research Professor, AD is an NIHR senior investigator and DA and PE are Emeritus NIHR Senior Investigators. SR acknowledges support from MRC Centre for Global Infectious Disease Analysis, National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU), Wellcome Trust (200861/Z/16/Z, 200187/Z/15/Z), and Centres for Disease Control and Prevention (US, U01CK0005-01-02). PE is Director of the MRC Centre for Environment and Health (MR/L01341X/1, MR/S019669/1). PE acknowledges support from the NIHR Imperial Biomedical Research Centre and the NIHR HPRUs in Chemical and Radiation Threats and Hazards and in Environmental Exposures and Health, the British Heart Foundation Centre for Research Excellence at Imperial College London (RE/18/4/34215), Health Data Research UK (HDR UK) and the UK Dementia Research Institute at Imperial (MC_PC_17114). We thank The Huo Family Foundation for their support of our work on COVID-19. SD acknowledges support from NIHR Biomedical Research Centre of Imperial College NHS Trust.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

We obtained research ethics approval from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787), and MHRA approval for use of the LFIA for research purposes only. The REACT Public Advisory Panel provides regular review of the study processes and results. The healthcare worker study was approved by the Health Research Authority, Research Ethics Committee (Reference: 20/WA/0123).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data analysed or used, or both, in this study are not publicly available owing to governance restrictions.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 01, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England
Helen Ward, Graham Cooke, Matthew Whitaker, Rozlyn Redd, Oliver Eales, Jonathan C Brown, Katharine Collet, Emily Cooper, Anna Daunt, Kathryn Jones, Maya Moshe, Michelle Willicombe, Sophie Day, Christina Atchison, Ara Darzi, Christl A Donnelly, Steven Riley, Deborah Ashby, Wendy S Barclay, Paul Elliott
medRxiv 2021.02.26.21252512; doi: https://doi.org/10.1101/2021.02.26.21252512
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England
Helen Ward, Graham Cooke, Matthew Whitaker, Rozlyn Redd, Oliver Eales, Jonathan C Brown, Katharine Collet, Emily Cooper, Anna Daunt, Kathryn Jones, Maya Moshe, Michelle Willicombe, Sophie Day, Christina Atchison, Ara Darzi, Christl A Donnelly, Steven Riley, Deborah Ashby, Wendy S Barclay, Paul Elliott
medRxiv 2021.02.26.21252512; doi: https://doi.org/10.1101/2021.02.26.21252512

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1778)
  • Dentistry and Oral Medicine (240)
  • Dermatology (173)
  • Emergency Medicine (317)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10834)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2968)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1938)
  • Health Policy (837)
  • Health Systems and Quality Improvement (747)
  • Hematology (295)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12535)
  • Intensive Care and Critical Care Medicine (697)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2819)
  • Nursing (152)
  • Nutrition (435)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (259)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (382)
  • Pediatrics (870)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (341)
  • Psychiatry and Clinical Psychology (2653)
  • Public and Global Health (5393)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (599)
  • Respiratory Medicine (729)
  • Rheumatology (330)
  • Sexual and Reproductive Health (294)
  • Sports Medicine (280)
  • Surgery (329)
  • Toxicology (48)
  • Transplantation (151)
  • Urology (127)